Clinical Trial Update: Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) [Phase 2]

View source ↗

Summary

Phase 2 study of burosumab (KRN23) in adults with tumor-induced osteomalacia or epidermal nevus syndrome has completed, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermal Nevus Syndrome
• Tumor-induced Osteomalacia

Drugs mentioned

• Burosumab (burosumab)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS) | Phase 2 | Status: COMPLETED | Results posted: 2020-07-30